FutureChem Co.,Ltd (KOSDAQ: 220100)

Market Cap	475.08B
Revenue (ttm)	14.92B
Net Income (ttm)	-8.73B
Shares Out	22.10M
EPS (ttm)	-394.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	397,669
Open	22,700
Previous Close	22,400
Day's Range	20,900 - 23,150
52-Week Range	7,690 - 25,650
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About FutureChem Co.,Ltd

FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1999
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 220100

Financial Performance

In 2023, FutureChem Co.,Ltd's revenue was 13.97 billion, an increase of 11.09% compared to the previous year's 12.57 billion. Losses were -6.71 billion, -51.94% less than in 2022.